TWST
Twist Bioscience Corporation · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 4.77K | $725,583 | n/a | n/a |
| Q2 2026 | 113 | +8 | 54.74M | $5.63B | +14 | −6 |
| Q1 2026 | 108 | +15 | 51.20M | $2.43B | +20 | −5 |
| Q4 2025 | 92 | -2 | 51.46M | $1.63B | +1 | −3 |
| Q3 2025 | 18 | 0 | 32.97M | $927.70M | +1 | −2 |
| Q2 2025 | 16 | -3 | 28.73M | $1.06B | n/a | −3 |
| Q1 2025 | 16 | +1 | 15.75M | $618.44M | +2 | −1 |
| Q4 2024 | 15 | 0 | 15.20M | $706.21M | n/a | n/a |
| Q3 2024 | 14 | +1 | 11.38M | $514.14M | +2 | −1 |
| Q2 2024 | 13 | n/a | 12.61M | $621.59M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 6.13M | n/a | $302.06M | 2.7% | n/c | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 1.43M | n/a | $70.36M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 1.34M | n/a | $66.13M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Baillie Gifford ✦ | 984.30K | n/a | $48.51M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 5 | Millennium Management ✦ | 782.38K | n/a | $38.56M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 673.06K | n/a | $33.17M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 579.23K | n/a | $28.54M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 276.46K | n/a | $13.62M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Norges Bank ✦ (passive) | 239.53K | n/a | $11.80M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Gotham Asset Management ✦ | 79.05K | n/a | $3.90M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 61.43K | n/a | $3.03M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | T. Rowe Price ✦ | 34.75K | n/a | $1.71M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 4.07K | n/a | $200,767 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 279 holders, 76.80M shares, $3.56B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.46K sh · $384,823
Officer, Director · 45 sh · $9,336
Officer, Director · 146 sh · $30,199
Officer, Director · 297 sh · $61,116
Officer, Director · 290 sh · $59,392
Officer, Director · 432 sh · $87,958
Officer, Director · 1.02K sh · $205,763
Officer, Director · 1.84K sh · $368,806
Officer, Director · 481 sh · $96,804
Officer · 25.71K sh · $4.86M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology